1
|
Mannerström B, Kornilov R, Abu-Shahba AG,
Chowdhury IM, Sinha S, Seppänen-Kaijansinkko R and Kaur S:
Epigenetic alterations in mesenchymal stem cells by
osteosarcoma-derived extracellular vesicles. Epigenetics.
14:352–364. 2019. View Article : Google Scholar
|
2
|
Brown HK, Tellez-Gabriel M and Heymann D:
Cancer stem cells in osteosarcoma. Cancer Lett. 386:189–195. 2017.
View Article : Google Scholar
|
3
|
Gross AC, Cam H, Phelps DA, Saraf AJ, Bid
HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, et al:
IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to
metastasis. JCI Insight. 3:e997912018. View Article : Google Scholar
|
4
|
Meazza C and Scanagatta P: Metastatic
osteosarcoma: A challenging multidisciplinary treatment. Expert Rev
Anticancer Ther. 16:543–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Haghiralsadat F, Amoabediny G,
Naderinezhad S, Zandieh-Doulabi B, Forouzanfar T and Helder MN:
Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted
PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug
resistance. Int J Nanomedicine. 13:3853–3866. 2018. View Article : Google Scholar : PubMed/NCBI
|
7
|
Sreeja S, Parameshwar R, Varma PRH and
Sailaja GS: Hierarchically porous osteoinductive Poly(hydroxyethyl
methacrylate-co-methyl methacrylate) scaffold with sustained
doxorubicin delivery for consolidated osteosarcoma treatment and
bone defect repair. ACS Biomater Sci Eng. 7:701–717. 2021.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Xu M, Li H, Zhai D, Chang J, Chen S and Wu
C: Hierarchically porous nagelschmidtite bioceramic-silk scaffolds
for bone tissue engineering. J Mater Chem B. 3:3799–3809. 2015.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Torres AL, Gaspar VM, Serra IR, Diogo GS,
Fradique R, Silva AP and Correia IJ: Bioactive polymeric-ceramic
hybrid 3D scaffold for application in bone tissue regeneration.
Mater Sci Eng C Mater Biol Appl. 33:4460–4469. 2013. View Article : Google Scholar
|
10
|
Zhu C, He M, Sun D, Huang Y, Huang L, Du
M, Wang J, Wang J, Li Z, Hu B, et al: 3D-Printed multifunctional
polyetheretherketone bone scaffold for multimodal treatment of
osteosarcoma and osteomyelitis. ACS Appl Mater Interfaces.
13:47327–47340. 2021. View Article : Google Scholar : PubMed/NCBI
|
11
|
Chou LF, Chen CY, Yang WH, Chen CC, Chang
JL, Leu YL, Liou MJ and Wang TH: Suppression of hepatocellular
carcinoma progression through FOXM1 and EMT inhibition via
hydroxygenkwanin-induced miR-320a expression. Biomolecules.
10:202019. View Article : Google Scholar
|
12
|
Chen YY, Tang YP, Shang EX, Zhu ZH, Tao
WW, Yu JG, Feng LM, Yang J, Wang J, Su SL, et al: Incompatibility
assessment of genkwa flos and glycyrrhizae radix et Rhizoma with
biochemical, histopathological and metabonomic approach. J
Ethnopharmacol. 229:222–232. 2019. View Article : Google Scholar
|
13
|
Li Y, Geng L, Liu Y, Chen M, Mu Q, Zhang
X, Zhang Z, Ren G and Liu C: Identification of three Daphne species
by DNA barcoding and HPLC fingerprint analysis. PLoS One.
13:e02017112018. View Article : Google Scholar : PubMed/NCBI
|
14
|
Wang L, Lan XY, Ji J, Zhang CF, Li F, Wang
CZ and Yuan CS: Anti-inflammatory and anti-angiogenic activities in
vitro of eight diterpenes from Daphne genkwa based on hierarchical
cluster and principal component analysis. J Nat Med. 72:675–685.
2018. View Article : Google Scholar : PubMed/NCBI
|
15
|
Li S, Chou G, Hseu Y, Yang H, Kwan H and
Yu Z: Isolation of anticancer constituents from flos genkwa (Daphne
genkwa Sieb.et Zucc.) through bioassay-guided procedures. Chem Cent
J. 7:1592013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Li YN, Yin LH, Xu LN and Peng JY: A simple
and efficient protocol for large-scale preparation of three
flavonoids from the flower of Daphne genkwa by combination of
macroporous resin and counter-current chromatography. J Sep Sci.
33:2168–2175. 2010. View Article : Google Scholar
|
17
|
Chen CY, Chen CC, Chuang WY, Leu YL, Ueng
SH, Hsueh C, Yeh CT and Wang TH: Hydroxygenkwanin inhibits class I
HDAC expression and synergistically enhances the antitumor activity
of sorafenib in liver cancer cells. Front Oncol. 10:2162020.
View Article : Google Scholar
|
18
|
Wang Y, Xu YS, Yin LH, Xu LN, Peng JY,
Zhou H and Kang W: Synergistic anti-glioma effect of
hydroxygenkwanin and apigenin in vitro. Chem Biol Interact.
206:346–355. 2013. View Article : Google Scholar
|
19
|
Correia de Sousa M, Gjorgjieva M, Dolicka
D, Sobolewski C and Foti M: Deciphering miRNAs' action through
miRNA editing. Int J Mol Sci. 20:62492019. View Article : Google Scholar
|
20
|
Di Leva G, Garofalo M and Croce CM:
MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar
|
21
|
Wang S, Lv S, Guan Y, Gao G, Li J, Hei F
and Long C: Cardiopulmonary bypass techniques and clinical outcomes
in Beijing Fuwai Hospital: A brief clinical review. ASAIO J.
57:414–420. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Ram Kumar RM, Boro A and Fuchs B:
Involvement and clinical aspects of MicroRNA in osteosarcoma. Int J
Mol Sci. 17:8772016. View Article : Google Scholar
|
23
|
Zhou B, Li L, Li Y, Sun H and Zeng C: Long
noncoding RNA SNHG12 mediates doxorubicin resistance of
osteosarcoma via miR-320a/MCL1 axis. Biomed Pharmacother.
106:850–857. 2018. View Article : Google Scholar : PubMed/NCBI
|
24
|
Huang S, Zhu X, Ke Y, Xiao D, Liang C,
Chen J and Chang Y: LncRNA FTX inhibition restrains osteosarcoma
proliferation and migration via modulating miR-320a/TXNRD1. Cancer
Biol Ther. 21:379–387. 2020. View Article : Google Scholar : PubMed/NCBI
|
25
|
Lefebvre V, Angelozzi M and Haseeb A: SOX9
in cartilage development and disease. Curr Opin Cell Biol.
61:39–47. 2019. View Article : Google Scholar
|
26
|
Zhang XD, Wang YN, Feng XY, Yang JY, Ge YY
and Kong WQ: Biological function of microRNA-30c/SOX9 in pediatric
osteosarcoma cell growth and metastasis. Eur Rev Med Pharmacol Sci.
22:70–78. 2018.
|
27
|
Zhang W, Wei L, Sheng W, Kang B, Wang D
and Zeng H: miR-1225-5p functions as a tumor suppressor in
osteosarcoma by targeting Sox9. DNA Cell Biol. 39:78–91. 2020.
View Article : Google Scholar
|
28
|
Ma L, Zhang L, Guo A, Liu LC, Yu F, Diao
N, Xu C and Wang D: Overexpression of FER1L4 promotes the apoptosis
and suppresses epithelial-mesenchymal transition and stemness
markers via activating PI3K/AKT signaling pathway in osteosarcoma
cells. Pathol Res Pract. 215:1524122019. View Article : Google Scholar
|
29
|
Qu H, Xue Y, Lian W, Wang C, He J, Fu Q,
Zhong L, Lin N, Lai L, Ye Z and Wang Q: Melatonin inhibits
osteosarcoma stem cells by suppressing SOX9-mediated signaling.
Life Sci. 207:253–264. 2018. View Article : Google Scholar
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Kai H, Koine T, Baba M and Okuyama T:
Pharmacological effects of Daphne genkwa and Chinese medical
prescription, ‘Jyu-So-To’. Yakugaku Zasshi. 124:349–354. 2004.(In
Japanese). View Article : Google Scholar
|
32
|
Chen Y, Guo J, Tang Y, Wu L, Tao W, Qian Y
and Duan JA: Pharmacokinetic profile and metabolite identification
of yuanhuapine, a bioactive component in Daphne genkwa by
ultra-high performance liquid chromatography coupled with tandem
mass spectrometry. J Pharm Biomed Anal. 112:60–69. 2015. View Article : Google Scholar
|
33
|
Huang YC, Lee PC, Wang JJ and Hsu YC:
Anticancer effect and mechanism of hydroxygenkwanin in oral
squamous cell carcinoma. Front Oncol. 9:9112019. View Article : Google Scholar
|
34
|
Villanueva F, Araya H, Briceño P, Varela
N, Stevenson A, Jerez S, Tempio F, Chnaiderman J, Perez C,
Villarroel M, et al: The cancer-related transcription factor RUNX2
modulates expression and secretion of the matricellular protein
osteopontin in osteosarcoma cells to promote adhesion to
endothelial pulmonary cells and lung metastasis. J Cell Physiol.
234:13659–13679. 2019. View Article : Google Scholar
|
35
|
Li C, Zhang S, Qiu T, Wang Y, Ricketts DM
and Qi C: Upregulation of long non-coding RNA NNT-AS1 promotes
osteosarcoma progression by inhibiting the tumor suppressive
miR-320a. Cancer Biol Ther. 20:413–422. 2019. View Article : Google Scholar : PubMed/NCBI
|
36
|
De-Ugarte L, Balcells S, Guerri-Fernandez
R, Grinberg D, Diez-Perez A, Nogues X and Garcia-Giralt N: Effect
of the tumor suppressor miR-320a on viability and functionality of
human osteosarcoma cell lines compared to primary osteoblasts. Appl
Sci. 10:28522020. View Article : Google Scholar
|
37
|
Lian F, Cui Y, Zhou C, Gao K and Wu L:
Identification of a plasma four-microRNA panel as potential
noninvasive biomarker for osteosarcoma. PLoS One. 10:e01214992015.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:(Database Issue). D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Yu M, Bardia A, Wittner BS, Stott SL, Smas
ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584. 2013.
View Article : Google Scholar : PubMed/NCBI
|